Clinilabs   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: New York NY United States (2000)

Organization Overview

First Clinical Trial
2006
NCT00972075
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Clinilabs Drug Development Corporation | Clinilabs, Inc | Clinilabs, Inc. | Clinilabs, Inc. 423 West 55th Street, 4th Floor New York, NY 10019 | Clinilabs, New York, NY

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Ataxia (Phase 1)

Blindness (Phase 2)

Cerebellar Ataxia (Phase 1)

Depression (Phase 2)

Depressive Disorder (Phase 2)

Depressive Disorder, Major (Phase 2)

Friedreich Ataxia (Phase 1)

HIV Infections (Phase 2)

Parasomnias (Phase 2)

Sleep Deprivation (Phase 2)

Sleep Disorders, Circadian Rhythm (Phase 2)

Sleep Initiation and Maintenance Disorders (Phase 3)

Sleep Wake Disorders (Phase 2)

Substance-Related Disorders (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 24
  • # of Trial APIs: 26